Jefferies Raises Tarsus Pharmaceuticals Target to $105 Following Strategic Acquisition

Key Facts

In a move reflecting optimism toward pipeline expansion in the biotech sector, Jefferies has raised its price target for Tarsus Pharmaceuticals to $105.00, implying a potential upside of 17.1%. This update follows Tarsus's acquisition of Alkeus Pharmaceuticals, a deal that granted the company worldwide rights to gildeuretinol for the treatment of Stargardt's disease. Clinical results from the TEASE-1 study demonstrated a significant reduction in retinal lesion growth and good tolerability, bolstering the drug's path toward potential approval.

According to analyst reports, Tarsus Pharmaceuticals holds a market capitalization of approximately $3.84 billion, with the stock maintaining a 52-week trading range between $48.20 and $91.53. The strategic purchase aims to address a critical unmet medical need, as there is currently no FDA-approved therapy for Stargardt's disease, a condition that can lead to blindness. This acquisition strengthens the company's leadership in the specialized eye care industry by adding a Phase 3 oral medicine to its developmental pipeline.

With real-time price data for TARS unavailable as of the September 8, 2026 close, investors are focusing on regulatory milestones for gildeuretinol as the primary forward catalyst. While the immediate economic calendar lacks direct biotech events, broader market sentiment may be influenced by upcoming US Factory Orders and the Federal Reserve's Beige Book, which could impact risk appetite for mid-cap biotechnology stocks.